Interaction potential of etravirine with drug transporters assessed in vitro

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1282-1284

  Zembruski, Nadine Cécile Luise ^a   Haefeli, Walter Emil ^a   Weiss, Johanna ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ETRAVIRINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PREGNANE X RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG TRANSPORT; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79952355540     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01527-10     Document Type: Article

References (27)

1. Andries, K., et al. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Azijn, H., et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
3. Bierman, W. F. W., et al. 2010. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J. Antimicrob. Chemother. 65:1672-1680.
4. Brown, K. C., S. Paul, and A. D. Kashuba. 2009. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48:211-241.
5. Dickinson, L., S. Khoo, and D. Back. 2010. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. 85:176-189.
6. Dixit, V., et al. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35:1853-1859.
7. Evers, R., et al. 1997. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 419:112-116. (Pubitemid 28011228)
8. Evers, R., et al. 1998. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:1310-1319.
9. Huisman, M. T., et al. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301. (Pubitemid 35449015)
10. Huisman, M. T., J. W. Smit, and A. H. Schinkel. 2000. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:237-242.
11. Jones, K., et al. 2001. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
12. Kakuda, T. N., M. Schöller-Gyüre, and R. M. W. Hoetelmans. 2010. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir. Ther. 15:817-829.
13. König, S. J., et al. 2010. Impact of drug transporters for the cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 11:2319-2328.
14. Mallolas, J., et al. 2007. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med. 8:131-134. (Pubitemid 46390850)
15. Martínez, E., and M. Nelson. 2010. Simplification of antiretroviral therapy with etravirine. AIDS Rev. 12:52-59.
16. Niemi, M. 2007. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802. (Pubitemid 47288978)
17. Pavek, P., et al. 2005. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312:144-152.
18. Schöller-Gyüre, M., et al. 2010. Effects of hepatic impairment on the steadystate pharmacokinetics of etravirine 200 mg BID: an open-label, multipledose, controlled phase I study in adults. Clin. Ther. 32:328-337.
19. Schöller-Gyüre, M., et al. 2008. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol. 48:322-329.
20. Su, Y., X. Zhang, and P. J. Sinko. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol. Pharm. 1:49-56.
21. Tan, K. P., et al. 2010. Aryl hydrocarbon receptor is a transcriptional activator of the human breast. Mol. Pharmacol. 78:175-185.
22. Tibotec Pharmaceuticals, Ltd. July 2010. Full prescribing information Intelence (etravirine) tablets. Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P., Raritan, NJ.
23. Weiss, J., et al. 2003. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther. 305:197-204.
24. Weiss, J., and W. E. Haefeli. 2010. Impact of ATP-binding cassette transporters on human immunodeficiency virus. Int. Rev. Cell Mol. Biol. 280:219-279.
25. Weiss, J., et al. 2010. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm. Drug Dispos. 31:150-161.
26. Zembruski, N., et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J. Antimicrob. Chemother., in press.
27. Zhang, L., Y. D. Zhang, J. M. Strong, K. S. Reynolds, and S.-M. Huang. 2008. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.